AbbVie Gets FDA OK for Pediatric Skin Infection Drug
July 23 2021 - 01:27PM
Dow Jones News
By Kimberly Chin
AbbVie Inc. received U.S. Food and Drug Administration approval
for its treatment of acute bacterial skin and skin structure
infections in children and infants, the company said Friday.
The Dalvance drug is administered intravenously in a single
dose. In clinical trials, the treatment was found to reduce lesion
size and didn't require rescue antibacterial therapy for children 3
months and older, the company said. The treatment's safety findings
in pediatric patients were also similar to those seen in adults, it
said.
Such skin infections are caused by Gram-positive pathogens, such
as Staphylococcus aureus and Streptococcus pyogenes, and they can
be serious and life-threatening, AbbVie said.
AbbVie's shares inched up nearly 1% on Friday to around $118.
Its stock has gained 21% in the past 12 months.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
July 23, 2021 13:18 ET (17:18 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Feb 2024 to Mar 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2023 to Mar 2024